Year: 2024

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-end Strong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific Sessions Actively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002’s potential to be a functional cure for HAE On track to dose the first patient by year-end in the Phase 1/2 study of NTLA-3001, an in vivo gene insertion candidate...

– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the...

On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. “The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025,” said Cingulate Chairman and CEO Shane J. Schaffer. “The granting of European patents for CTx-1301 in up to 30 territories, including the United Kingdom,...

Investor Call Today at 11am ET; Dial-in: 1-844-834-0644 WILMINGTON, Del., Nov. 07, 2024 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its third quarter ended September 30, 2024 (Q3’24) and will hold an investor call today at 11am ET (see call details below). Summary Financial Results($ in thousands) Q3’24   Q3’23   Change   9M’24   9M’23   ChangeMonitoring revenue $ 1,138   $ 1,083   +5.1 %   $ 3,350   $ 3,172   +5.6 %Hardware revenue $ 1,912   $ 1,004   +90.4 %   $ 4,107   $ 2,637   +55.7 %Total revenue (1) $ 3,050   $ 2,087   +46.1 %   $ 7,457   $ 5,809   +28.4 %Gross margin   71.7%     74.3%         73.0%     75.0%    Net income...

Third Quarter Net Revenue of $145.0 million, up 31.3% versus Prior Year PeriodRaises Fiscal Year 2024 Guidance and Reiterates Long-term GuidanceOn Track to Reach $1 Billion Net Revenue Target in 2027 AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its third quarter ended September 29, 2024. Financial highlights for the third quarter ended September 29, 2024, compared to the third quarter ended September 24, 2023, include:Net Revenue increased 31.3% to $145.0 million, compared to $110.4 million Gross Margin expanded 368 basis points to 36.9%, compared to 33.2% Net Income of $7.4 million, compared to $4.5 million Net Income per Diluted Share of $0.16, compared to $0.10 Adjusted EBITDA...

– Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the “Combination”) – – Expanded pipeline with multiple programs in large markets with high unmet need – – Strategic financing results in combined working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development through 2025 – – Top-line results from Long-COVID Phase 2a study expected in mid-November 2024 – – NaV 1.7 inhibition pain treatment, Halneuron®, Phase 2b study for chemotherapy-induced neuropathic pain expected interim readout 2H 2025 – ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”),...

Third quarter cloud subscription revenue increased 22% year-over-year to $94.1 million MCLEAN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2024. “Appian continues to grow even as we become more efficient. Growth remains our top priority. We now project positive adjusted EBITDA for the full year 2024,” said Matt Calkins, CEO & Founder. Third Quarter 2024 Financial Highlights:Revenue: Cloud subscription revenue was $94.1 million, up 22% compared to the third quarter of 2023. Total subscriptions revenue, which includes sales of our cloud subscriptions, on-premises term license subscriptions, and maintenance and support, increased 19% year-over-year to $123.1 million. Professional services revenue was $30.9 million, a decrease of 7% compared...

CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates$2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the “Amendment”) to its existing ex-US royalty financing with R-Bridge Healthcare Fund (“R-Bridge”). The Company is further eligible to receive up to an additional $8 million based on future milestones. As part of the Amendment, (i) certain OLINVYK Chinese...